Hereditary Angioedema Market Snapshot: Room For Pills And Injections As Prophylaxis Makes Gains

 
• By Ayisha Sharma
  
Generate a summary of this article
Listen to this article
Beta

While many HAE patients converted from injectable prophylaxis to BioCryst’s oral Orladeyo last year, physicians said a promising injectable candidate from Ionis could benefit from varied patient preference.  

Dozens of colourful balloons are released into the sky at the International Rare Disease Day in Sofia, Bulgaria
Hereditary Angioedema Is a Rare Disease That Causes Extreme Swelling • Source: Alamy

The hereditary angioedema (HAE) market was shaken up last year by the launch of BioCryst Pharmaceuticals, Inc.’s plasma kallikrein inhibitor Orladeyo (berotralstat), the first oral prophylactic. Patients were previously limited to prophylactics with a more burdensome route of administration, such as Takeda Pharmaceutical Co. Ltd.’s subcutaneous plasma kallikrein inhibitor Takhzyro (lanadelumab).

HAE involves repeat episodes of swelling in the face, airway, limbs and intestines, causing vomiting, severe pain and even death...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Market Snapshot

Myeloma Market Snapshot: New Drug Classes On The Way, But Cost Could Be A Problem

 
• By Alaric DeArment

More BCMA-directed therapies are in development, as well as ones targeting GPRC5D and FcRH5, along with CELMoDs. The question is how to bring those into therapy and pay for them.

Myeloma Market Snapshot: Backlogs Dog BCMA CAR-Ts As Treatment Paradigm Evolves

 
• By Alaric DeArment

KOLs told Scrip about how they are incorporating new immunotherapies into treatment and combining existing agents, but some new drug classes have struggled to take root.

IBD Market Snapshot: Payers May Shift Preferred Products To Accommodate New Drugs

 
• By Mandy Jackson

Multi-product players may be able to use bundled rebates for preferred formulary status and biosimilars offer a new competitive dynamic, but there is hope for novel therapies.

IBD Market Snapshot: New Medicines Try To Address Patient, Physician Demands

 
• By Mandy Jackson

Remission rates with existing therapies leave much room for improvement, so a variety of treatments are needed – leaving major players attempting to carve unique paths in a crowded market.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains